I期非小细胞肺癌的治疗方案应考虑病变的极大化。

IF 2.5 4区 医学 Q2 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Annals of Nuclear Medicine Pub Date : 2025-08-01 Epub Date: 2025-04-10 DOI:10.1007/s12149-025-02049-0
Gökhan Kocaman, Farrukh Ibrahımov, Yusuf Kahya, Mine Araz, Atilla Halil Elhan, Serkan Enön
{"title":"I期非小细胞肺癌的治疗方案应考虑病变的极大化。","authors":"Gökhan Kocaman, Farrukh Ibrahımov, Yusuf Kahya, Mine Araz, Atilla Halil Elhan, Serkan Enön","doi":"10.1007/s12149-025-02049-0","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>High maximum standardized uptake value (SUVmax) is associated with poorly differentiated tumors and lymph node metastasis. It is still controversial which tumors can be treated with sublobar resection and there are publications stating that SUVmax of the tumor may be important in choosing sublobar resection. Our aim in this study is to examine the prognostic value of tumor SUVmax in stage 1 non-small cell lung cancer and to determine its place in sublobar resection preference.</p><p><strong>Methods: </strong>The study included 314 patients who underwent wedge resection, segmentectomy or lobectomy for pathological stage I NSCLC with tumor size ≤ 3 cm between January 2008 and December 2020. SUVmax of the tumors are dichotomized according to ROC threshold value 5.2 and prognostic factors for recurrence-free and overall survival were analysed.</p><p><strong>Results: </strong>In the multivariate survival analysis, SUVmax (p = 0.012), lymphovascular and/or perineural invasion (p < 0.001) and visceral pleural invasion (p = 0.031) were found to be independent prognostic factors for recurrence-free survival; age (p = 0.027), sex (p = 0.010) and SUVmax (p = 0.036) for overall survival. While there was no difference between lobar or sublobar resection in terms of recurrence-free survival (p = 0.647) in patients with SUVmax ≤ 5.2, lobectomy was found to be advantageous over sublobar resection for recurrence-free survival in patients with SUVmax > 5.2 (76.6% ± 3.9% / 53.4% ± 12.1%, p = 0.006, respectively).</p><p><strong>Conclusions: </strong>High SUVmax (> 5.2) is associated with poor recurrence-free survival and overall survival rates in pathological stage 1 NSCLC patients. In stage 1 patients, sublobar resection should be avoided if the primary tumor has a high SUVmax.</p>","PeriodicalId":8007,"journal":{"name":"Annals of Nuclear Medicine","volume":" ","pages":"792-798"},"PeriodicalIF":2.5000,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289744/pdf/","citationCount":"0","resultStr":"{\"title\":\"Suvmax of the lesion should be considered in the treatment plan for stage I non-small cell lung cancer.\",\"authors\":\"Gökhan Kocaman, Farrukh Ibrahımov, Yusuf Kahya, Mine Araz, Atilla Halil Elhan, Serkan Enön\",\"doi\":\"10.1007/s12149-025-02049-0\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objectives: </strong>High maximum standardized uptake value (SUVmax) is associated with poorly differentiated tumors and lymph node metastasis. It is still controversial which tumors can be treated with sublobar resection and there are publications stating that SUVmax of the tumor may be important in choosing sublobar resection. Our aim in this study is to examine the prognostic value of tumor SUVmax in stage 1 non-small cell lung cancer and to determine its place in sublobar resection preference.</p><p><strong>Methods: </strong>The study included 314 patients who underwent wedge resection, segmentectomy or lobectomy for pathological stage I NSCLC with tumor size ≤ 3 cm between January 2008 and December 2020. SUVmax of the tumors are dichotomized according to ROC threshold value 5.2 and prognostic factors for recurrence-free and overall survival were analysed.</p><p><strong>Results: </strong>In the multivariate survival analysis, SUVmax (p = 0.012), lymphovascular and/or perineural invasion (p < 0.001) and visceral pleural invasion (p = 0.031) were found to be independent prognostic factors for recurrence-free survival; age (p = 0.027), sex (p = 0.010) and SUVmax (p = 0.036) for overall survival. While there was no difference between lobar or sublobar resection in terms of recurrence-free survival (p = 0.647) in patients with SUVmax ≤ 5.2, lobectomy was found to be advantageous over sublobar resection for recurrence-free survival in patients with SUVmax > 5.2 (76.6% ± 3.9% / 53.4% ± 12.1%, p = 0.006, respectively).</p><p><strong>Conclusions: </strong>High SUVmax (> 5.2) is associated with poor recurrence-free survival and overall survival rates in pathological stage 1 NSCLC patients. In stage 1 patients, sublobar resection should be avoided if the primary tumor has a high SUVmax.</p>\",\"PeriodicalId\":8007,\"journal\":{\"name\":\"Annals of Nuclear Medicine\",\"volume\":\" \",\"pages\":\"792-798\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12289744/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annals of Nuclear Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12149-025-02049-0\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/4/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12149-025-02049-0","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/10 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

摘要

目的:较高的最大标准化摄取值(SUVmax)与低分化肿瘤和淋巴结转移有关。对于哪些肿瘤可以用叶下切除术治疗仍然存在争议,有出版物指出肿瘤的SUVmax可能是选择叶下切除术的重要因素。我们在这项研究中的目的是检查肿瘤SUVmax在1期非小细胞肺癌中的预后价值,并确定其在叶下切除首选中的地位。方法:本研究纳入了2008年1月至2020年12月期间314例肿瘤大小≤3cm的病理I期NSCLC患者行楔形切除术、节段切除术或肺叶切除术。根据ROC阈值5.2对肿瘤的SUVmax进行二分类,分析无复发和总生存的预后因素。结果:在多因素生存分析中,SUVmax (p = 0.012)、淋巴血管和/或神经周围浸润(p = 5.2)(76.6%±3.9% / 53.4%±12.1%,p = 0.006)。结论:在病理1期NSCLC患者中,高SUVmax(> 5.2)与较差的无复发生存率和总生存率相关。在1期患者中,如果原发肿瘤有很高的SUVmax,则应避免进行叶下切除术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Suvmax of the lesion should be considered in the treatment plan for stage I non-small cell lung cancer.

Objectives: High maximum standardized uptake value (SUVmax) is associated with poorly differentiated tumors and lymph node metastasis. It is still controversial which tumors can be treated with sublobar resection and there are publications stating that SUVmax of the tumor may be important in choosing sublobar resection. Our aim in this study is to examine the prognostic value of tumor SUVmax in stage 1 non-small cell lung cancer and to determine its place in sublobar resection preference.

Methods: The study included 314 patients who underwent wedge resection, segmentectomy or lobectomy for pathological stage I NSCLC with tumor size ≤ 3 cm between January 2008 and December 2020. SUVmax of the tumors are dichotomized according to ROC threshold value 5.2 and prognostic factors for recurrence-free and overall survival were analysed.

Results: In the multivariate survival analysis, SUVmax (p = 0.012), lymphovascular and/or perineural invasion (p < 0.001) and visceral pleural invasion (p = 0.031) were found to be independent prognostic factors for recurrence-free survival; age (p = 0.027), sex (p = 0.010) and SUVmax (p = 0.036) for overall survival. While there was no difference between lobar or sublobar resection in terms of recurrence-free survival (p = 0.647) in patients with SUVmax ≤ 5.2, lobectomy was found to be advantageous over sublobar resection for recurrence-free survival in patients with SUVmax > 5.2 (76.6% ± 3.9% / 53.4% ± 12.1%, p = 0.006, respectively).

Conclusions: High SUVmax (> 5.2) is associated with poor recurrence-free survival and overall survival rates in pathological stage 1 NSCLC patients. In stage 1 patients, sublobar resection should be avoided if the primary tumor has a high SUVmax.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Annals of Nuclear Medicine
Annals of Nuclear Medicine 医学-核医学
CiteScore
4.90
自引率
7.70%
发文量
111
审稿时长
4-8 weeks
期刊介绍: Annals of Nuclear Medicine is an official journal of the Japanese Society of Nuclear Medicine. It develops the appropriate application of radioactive substances and stable nuclides in the field of medicine. The journal promotes the exchange of ideas and information and research in nuclear medicine and includes the medical application of radionuclides and related subjects. It presents original articles, short communications, reviews and letters to the editor.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信